Showing 1 - 12 results of 12 for search 'Christina Charles-Schoeman', query time: 0.04s Refine Results
  1. 1
    Altered Gut Microbiome in Patients With Dermatomyositis

    Altered Gut Microbiome in Patients With Dermatomyositis by Sangmee Sharon Bae, Tien S. Dong, Jennifer Wang, Venu Lagishetty, William Katzka, Jonathan P. Jacobs, Christina Charles‐Schoeman

    Published 2022-08-01
    Get full text
    Article
  2. 2
    Plasma levels of adhesion molecules are elevated in dermatomyositis-interstitial lung disease and associated with low paraoxonase-1 activity

    Plasma levels of adhesion molecules are elevated in dermatomyositis-interstitial lung disease and associated with low paraoxonase-1 activity by Sangmee Sharon Bae, Ani Shahbazian, Jennifer Wang, Daniela Markovic, Tiffany De Leon, Yuna Lee, Srinivasa T. Reddy, Christina Charles-Schoeman

    Published 2025-03-01
    Get full text
    Article
  3. 3
    Association between low hemoglobin, clinical measures, and patient-reported outcomes in patients with rheumatoid arthritis: results from post hoc analyses of three phase III trials of sarilumab

    Association between low hemoglobin, clinical measures, and patient-reported outcomes in patients with rheumatoid arthritis: results from post hoc analyses of three phase III trials... by Andrea Rubbert-Roth, Daniel E. Furst, Stefano Fiore, Amy Praestgaard, Vivian Bykerk, Clifton O. Bingham, Christina Charles-Schoeman, Gerd Burmester

    Published 2022-08-01
    Get full text
    Article
  4. 4
    Efficacy and safety of upadacitinib in patients with rheumatoid arthritis and inadequate response or intolerance to biological treatments: results through 5 years from the SELECT-BEYOND study

    Efficacy and safety of upadacitinib in patients with rheumatoid arthritis and inadequate response or intolerance to biological treatments: results through 5 years from the SELECT-B... by Roy Fleischmann, Stephen Hall, Bernard Combe, Andrea Rubbert-Roth, Christina Charles-Schoeman, Nasser Khan, Heidi S Camp, Sebastian Meerwein, Kyle M Carter

    Published 2024-07-01
    Get full text
    Article
  5. 5
    Biomarkers to predict risk of venous thromboembolism in patients with rheumatoid arthritis receiving tofacitinib or tumour necrosis factor inhibitors

    Biomarkers to predict risk of venous thromboembolism in patients with rheumatoid arthritis receiving tofacitinib or tumour necrosis factor inhibitors by Zoltan Szekanecz, Zhenyu Wang, Jeffrey I Weitz, Christina Charles-Schoeman, Ivana Vranic, David A Martin, Craig Hyde, Burak Sahin, Sara A Paciga

    Published 2022-11-01
    Get full text
    Article
  6. 6
    MACE and VTE across upadacitinib clinical trial programmes in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis

    MACE and VTE across upadacitinib clinical trial programmes in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis by Peter Nash, Iain B McInnes, Ernest Choy, Jeffrey R Curtis, Eduardo Mysler, Christina Charles-Schoeman, Nasser Khan, Kunihiro Yamaoka, Ralph Lippe, Hannah Palac, Anna K Shmagel, Jessica Suboticki

    Published 2023-10-01
    Get full text
    Article
  7. 7
    Risk of extended major adverse cardiovascular event endpoints with tofacitinib versus TNF inhibitors in patients with rheumatoid arthritis: a post hoc analysis of a phase 3b/4 randomised safety study

    Risk of extended major adverse cardiovascular event endpoints with tofacitinib versus TNF inhibitors in patients with rheumatoid arthritis: a post hoc analysis of a phase 3b/4 rand... by Arne Yndestad, Maya H Buch, Carol A Connell, Kenneth Kwok, Ted Mikuls, Deepak L Bhatt, Jon T Giles, Christina Charles-Schoeman, Gary G Koch, Edward Nagy, Steven Ytterberg, Hyejin Jo, Karim Richard Masri

    Published 2024-05-01
    Get full text
    Article
  8. 8
    Safety and tolerability of intravenous immunoglobulin in patients with active dermatomyositis: results from the randomised, placebo-controlled ProDERM study

    Safety and tolerability of intravenous immunoglobulin in patients with active dermatomyositis: results from the randomised, placebo-controlled ProDERM study by Rohit Aggarwal, Joachim Schessl, Christina Charles-Schoeman, Zsuzsanna Bata-Csörgő, Mazen M. Dimachkie, Zoltan Griger, Sergey Moiseev, Chester V. Oddis, Elena Schiopu, Jiri Vencovský, Irene Beckmann, Elisabeth Clodi, Todd Levine, the ProDERM investigators

    Published 2024-01-01
    Get full text
    Article
  9. 9
    Disease response in rheumatoid arthritis across four biologic therapies associates with improvement in paraoxonase-1 activity and oxylipins

    Disease response in rheumatoid arthritis across four biologic therapies associates with improvement in paraoxonase-1 activity and oxylipins by Jeffrey R Curtis, Jennifer Wang, Joel M Kremer, Srinivasa T Reddy, Dimitrios A Pappas, Christina Charles-Schoeman, David A Elashoff, Rong Guo, Amir A Razmjou, Ani Shahbazian, David Meriwether, Dawoud Sulaiman, Ellen O'Connor

    Published 2024-10-01
    Get full text
    Article
  10. 10
    Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme

    Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme by Peter Nash, Yoshiya Tanaka, Kevin L Winthrop, Eun Bong Lee, Xavier Mariette, Jeffrey R Curtis, Kenneth Kwok, Connie Chen, Pinaki Biswas, Lisy Wang, Christina Charles-Schoeman, Ann Madsen, Stanley B Cohen, Andrea Shapiro, Jürgen Wollenhaupt

    Published 2020-10-01
    Get full text
    Article
  11. 11
    Impact of Upadacitinib on Laboratory Parameters and Related Adverse Events in Patients with RA: Integrated Data Up to 6.5 Years

    Impact of Upadacitinib on Laboratory Parameters and Related Adverse Events in Patients with RA: Integrated Data Up to 6.5 Years by Christina Charles-Schoeman, Jon T. Giles, Nancy E. Lane, Ernest Choy, Daniel E. Furst, Jiří Vencovský, Anthony G. Wilson, Gerd R. Burmester, Derek Coombs, Sara K. Penn, Nasser Khan, Jillian B. Yee, Kassim Rahawi, Iain B. McInnes

    Published 2024-01-01
    Get full text
    Article
  12. 12
    Major adverse cardiovascular, thromboembolic and malignancy events in the filgotinib rheumatoid arthritis and ulcerative colitis clinical development programmes

    Major adverse cardiovascular, thromboembolic and malignancy events in the filgotinib rheumatoid arthritis and ulcerative colitis clinical development programmes by Zoltan Szekanecz, Yoshiya Tanaka, Laurent Peyrin-Biroulet, Stefan Schreiber, René Westhovens, Xavier Mariette, Chris Watson, C Janneke van der Woude, Hugo ten Cate, Andreas Stallmach, Christina Charles-Schoeman, Sandrine Aspeslagh, Marc Schmalzing, Margaux Faes, Sven Borchmann, Christine Rudolph, Edmund V Ekoka Omoruyi, Paul Van Hoek, Ernest HS Choy, Tomasz Masior

    Published 2025-03-01
    Get full text
    Article

Search Tools: